CN112639470A - 淀粉样物质相关疾病的诊断方法 - Google Patents
淀粉样物质相关疾病的诊断方法 Download PDFInfo
- Publication number
- CN112639470A CN112639470A CN201980035259.0A CN201980035259A CN112639470A CN 112639470 A CN112639470 A CN 112639470A CN 201980035259 A CN201980035259 A CN 201980035259A CN 112639470 A CN112639470 A CN 112639470A
- Authority
- CN
- China
- Prior art keywords
- amyloid
- sample
- aggregates
- individual
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 217
- 201000010099 disease Diseases 0.000 title claims abstract description 205
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 205
- 238000003745 diagnosis Methods 0.000 claims abstract description 62
- 238000004393 prognosis Methods 0.000 claims abstract description 58
- 239000013543 active substance Substances 0.000 claims abstract description 35
- 239000000523 sample Substances 0.000 claims description 282
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 142
- 102000004169 proteins and genes Human genes 0.000 claims description 124
- 108090000623 proteins and genes Proteins 0.000 claims description 124
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 116
- JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 claims description 95
- 238000001514 detection method Methods 0.000 claims description 94
- 208000024827 Alzheimer disease Diseases 0.000 claims description 82
- 210000002966 serum Anatomy 0.000 claims description 80
- 239000003795 chemical substances by application Substances 0.000 claims description 65
- 210000001124 body fluid Anatomy 0.000 claims description 64
- 238000002060 fluorescence correlation spectroscopy Methods 0.000 claims description 58
- 238000004458 analytical method Methods 0.000 claims description 57
- 238000005259 measurement Methods 0.000 claims description 50
- 238000012360 testing method Methods 0.000 claims description 47
- 238000011282 treatment Methods 0.000 claims description 45
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 43
- 239000013068 control sample Substances 0.000 claims description 37
- 210000004369 blood Anatomy 0.000 claims description 32
- 239000008280 blood Substances 0.000 claims description 31
- 239000012530 fluid Substances 0.000 claims description 28
- 239000002245 particle Substances 0.000 claims description 25
- 210000002381 plasma Anatomy 0.000 claims description 23
- 239000010839 body fluid Substances 0.000 claims description 22
- 208000010877 cognitive disease Diseases 0.000 claims description 22
- 238000003556 assay Methods 0.000 claims description 18
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 claims description 18
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 claims description 18
- 239000011714 flavin adenine dinucleotide Substances 0.000 claims description 18
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 claims description 18
- 210000002700 urine Anatomy 0.000 claims description 17
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 15
- 210000003296 saliva Anatomy 0.000 claims description 15
- 102000001049 Amyloid Human genes 0.000 claims description 14
- 108010094108 Amyloid Proteins 0.000 claims description 14
- 238000001506 fluorescence spectroscopy Methods 0.000 claims description 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 14
- 210000000265 leukocyte Anatomy 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 108090000790 Enzymes Proteins 0.000 claims description 13
- 206010002022 amyloidosis Diseases 0.000 claims description 13
- -1 dicyanovinyl Chemical group 0.000 claims description 13
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims description 12
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims description 12
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 11
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 11
- 230000003321 amplification Effects 0.000 claims description 11
- 238000000338 in vitro Methods 0.000 claims description 11
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 11
- 241000283690 Bos taurus Species 0.000 claims description 10
- 241000283073 Equus caballus Species 0.000 claims description 10
- 208000034846 Familial Amyloid Neuropathies Diseases 0.000 claims description 10
- 206010019889 Hereditary neuropathic amyloidosis Diseases 0.000 claims description 10
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 10
- 201000007905 transthyretin amyloidosis Diseases 0.000 claims description 10
- 241000282414 Homo sapiens Species 0.000 claims description 9
- 210000001772 blood platelet Anatomy 0.000 claims description 9
- 208000018737 Parkinson disease Diseases 0.000 claims description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
- 239000013592 cell lysate Substances 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 210000003743 erythrocyte Anatomy 0.000 claims description 8
- 208000023105 Huntington disease Diseases 0.000 claims description 7
- 102000004877 Insulin Human genes 0.000 claims description 7
- 108090001061 Insulin Proteins 0.000 claims description 7
- 229940125396 insulin Drugs 0.000 claims description 7
- CYJJLCDCWVZEDZ-UHFFFAOYSA-N 8-aminonaphthalene-1-sulfonic acid Chemical compound C1=CC(S(O)(=O)=O)=C2C(N)=CC=CC2=C1 CYJJLCDCWVZEDZ-UHFFFAOYSA-N 0.000 claims description 6
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims description 6
- 102000019034 Chemokines Human genes 0.000 claims description 6
- 108010012236 Chemokines Proteins 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- 108091006725 SLCO1C1 Proteins 0.000 claims description 6
- 102100027229 Solute carrier organic anion transporter family member 1C1 Human genes 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 241000282465 Canis Species 0.000 claims description 5
- 241000282472 Canis lupus familiaris Species 0.000 claims description 5
- 241000700198 Cavia Species 0.000 claims description 5
- 241000282693 Cercopithecidae Species 0.000 claims description 5
- 241000699800 Cricetinae Species 0.000 claims description 5
- 241000282324 Felis Species 0.000 claims description 5
- 241000282326 Felis catus Species 0.000 claims description 5
- 241000699694 Gerbillinae Species 0.000 claims description 5
- 241001272567 Hominoidea Species 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 5
- 241000699670 Mus sp. Species 0.000 claims description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 5
- 241000700159 Rattus Species 0.000 claims description 5
- 241000283984 Rodentia Species 0.000 claims description 5
- 241000282887 Suidae Species 0.000 claims description 5
- 201000004810 Vascular dementia Diseases 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 210000001179 synovial fluid Anatomy 0.000 claims description 5
- 208000023761 AL amyloidosis Diseases 0.000 claims description 4
- 208000028698 Cognitive impairment Diseases 0.000 claims description 4
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 4
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 4
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 4
- 241000288906 Primates Species 0.000 claims description 4
- 102000003946 Prolactin Human genes 0.000 claims description 4
- 108010057464 Prolactin Proteins 0.000 claims description 4
- 230000001746 atrial effect Effects 0.000 claims description 4
- 229940097325 prolactin Drugs 0.000 claims description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
- 206010016202 Familial Amyloidosis Diseases 0.000 claims description 3
- 201000004176 Gelatinous drop-like corneal dystrophy Diseases 0.000 claims description 3
- 101000945751 Homo sapiens Leukocyte cell-derived chemotaxin-2 Proteins 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 102100034762 Leukocyte cell-derived chemotaxin-2 Human genes 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 claims description 3
- 206010036105 Polyneuropathy Diseases 0.000 claims description 3
- 201000007902 Primary cutaneous amyloidosis Diseases 0.000 claims description 3
- 208000024777 Prion disease Diseases 0.000 claims description 3
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 3
- LROAUBRDKLVBCP-UHFFFAOYSA-N dcvj Chemical compound C1CCC2=CC(C=C(C#N)C#N)=CC3=C2N1CCC3 LROAUBRDKLVBCP-UHFFFAOYSA-N 0.000 claims description 3
- VWLWTJHKQHRTNC-UHFFFAOYSA-L dipotassium;8-anilino-5-(4-anilino-5-sulfonatonaphthalen-1-yl)naphthalene-1-sulfonate Chemical compound [K+].[K+].C=12C(S(=O)(=O)[O-])=CC=CC2=C(C=2C3=CC=CC(=C3C(NC=3C=CC=CC=3)=CC=2)S([O-])(=O)=O)C=CC=1NC1=CC=CC=C1 VWLWTJHKQHRTNC-UHFFFAOYSA-L 0.000 claims description 3
- 201000007891 familial visceral amyloidosis Diseases 0.000 claims description 3
- 238000001631 haemodialysis Methods 0.000 claims description 3
- 230000000322 hemodialysis Effects 0.000 claims description 3
- 208000017105 hereditary amyloidosis Diseases 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 201000006370 kidney failure Diseases 0.000 claims description 3
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims description 3
- 230000007824 polyneuropathy Effects 0.000 claims description 3
- 208000022256 primary systemic amyloidosis Diseases 0.000 claims description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 3
- 241000251468 Actinopterygii Species 0.000 claims description 2
- 241000244203 Caenorhabditis elegans Species 0.000 claims description 2
- 241000938605 Crocodylia Species 0.000 claims description 2
- 241000252212 Danio rerio Species 0.000 claims description 2
- 241000255601 Drosophila melanogaster Species 0.000 claims description 2
- 241000238631 Hexapoda Species 0.000 claims description 2
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 claims description 2
- 241000244206 Nematoda Species 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 241000269368 Xenopus laevis Species 0.000 claims description 2
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 238000009792 diffusion process Methods 0.000 description 31
- 102000013498 tau Proteins Human genes 0.000 description 19
- 108010026424 tau Proteins Proteins 0.000 description 19
- 150000001413 amino acids Chemical class 0.000 description 18
- 230000003287 optical effect Effects 0.000 description 18
- 229940024606 amino acid Drugs 0.000 description 17
- 230000008859 change Effects 0.000 description 16
- 230000008569 process Effects 0.000 description 16
- 230000006870 function Effects 0.000 description 14
- 239000000126 substance Substances 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 241000219739 Lens Species 0.000 description 12
- 239000007900 aqueous suspension Substances 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 229910052751 metal Inorganic materials 0.000 description 12
- 239000002184 metal Substances 0.000 description 12
- 239000000090 biomarker Substances 0.000 description 11
- VYXSBFYARXAAKO-WTKGSRSZSA-N chembl402140 Chemical compound Cl.C1=2C=C(C)C(NCC)=CC=2OC2=C\C(=N/CC)C(C)=CC2=C1C1=CC=CC=C1C(=O)OCC VYXSBFYARXAAKO-WTKGSRSZSA-N 0.000 description 11
- 238000007405 data analysis Methods 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- 230000004770 neurodegeneration Effects 0.000 description 11
- 210000000601 blood cell Anatomy 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000035945 sensitivity Effects 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 238000005311 autocorrelation function Methods 0.000 description 9
- 238000009826 distribution Methods 0.000 description 9
- 206010012289 Dementia Diseases 0.000 description 8
- 230000002776 aggregation Effects 0.000 description 8
- 238000004220 aggregation Methods 0.000 description 8
- 238000013399 early diagnosis Methods 0.000 description 8
- 230000000903 blocking effect Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000005670 electromagnetic radiation Effects 0.000 description 7
- 230000002123 temporal effect Effects 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 238000004164 analytical calibration Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 230000002045 lasting effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 5
- 238000000429 assembly Methods 0.000 description 5
- 230000000712 assembly Effects 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 238000002600 positron emission tomography Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000007704 transition Effects 0.000 description 5
- 206010061818 Disease progression Diseases 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 102400000524 Fibrinogen alpha chain Human genes 0.000 description 4
- 101710137044 Fibrinogen alpha chain Proteins 0.000 description 4
- 102000016943 Muramidase Human genes 0.000 description 4
- 108010014251 Muramidase Proteins 0.000 description 4
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 4
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 4
- 102100030098 Oncostatin-M-specific receptor subunit beta Human genes 0.000 description 4
- 101710121849 Oncostatin-M-specific receptor subunit beta Proteins 0.000 description 4
- 102000054727 Serum Amyloid A Human genes 0.000 description 4
- 101710190759 Serum amyloid A protein Proteins 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 230000005750 disease progression Effects 0.000 description 4
- 238000000799 fluorescence microscopy Methods 0.000 description 4
- 238000005286 illumination Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 229960000274 lysozyme Drugs 0.000 description 4
- 239000004325 lysozyme Substances 0.000 description 4
- 235000010335 lysozyme Nutrition 0.000 description 4
- 230000015654 memory Effects 0.000 description 4
- 150000002739 metals Chemical class 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229960001353 tafamidis Drugs 0.000 description 4
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 3
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 3
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 3
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 3
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 3
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 3
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 3
- 238000012935 Averaging Methods 0.000 description 3
- 102100021257 Beta-secretase 1 Human genes 0.000 description 3
- 101100020739 Caenorhabditis elegans lect-2 gene Proteins 0.000 description 3
- 206010018910 Haemolysis Diseases 0.000 description 3
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 description 3
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 3
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 3
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 3
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 3
- 230000003942 amyloidogenic effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000005350 fused silica glass Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- 229960004502 levodopa Drugs 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 206010027175 memory impairment Diseases 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000002096 quantum dot Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 239000012086 standard solution Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- TXEIIPDJKFWEEC-UHFFFAOYSA-N tafamidis Chemical compound O1C2=CC(C(=O)O)=CC=C2N=C1C1=CC(Cl)=CC(Cl)=C1 TXEIIPDJKFWEEC-UHFFFAOYSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 2
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 2
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 2
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 2
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 102000015833 Cystatin Human genes 0.000 description 2
- 108060003393 Granulin Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102100023350 Integral membrane protein 2B Human genes 0.000 description 2
- 101710180845 Integral membrane protein 2B Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 108010071690 Prealbumin Proteins 0.000 description 2
- 102000029797 Prion Human genes 0.000 description 2
- 108091000054 Prion Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 2
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 2
- 102000009190 Transthyretin Human genes 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 230000003941 amyloidogenesis Effects 0.000 description 2
- 208000013404 behavioral symptom Diseases 0.000 description 2
- 238000012742 biochemical analysis Methods 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000000544 cholinesterase inhibitor Substances 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000003930 cognitive ability Effects 0.000 description 2
- 108050004038 cystatin Proteins 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002189 fluorescence spectrum Methods 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 102000017941 granulin Human genes 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000012001 immunoprecipitation mass spectrometry Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 2
- 229960004640 memantine Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 230000004007 neuromodulation Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 238000000554 physical therapy Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 238000003118 sandwich ELISA Methods 0.000 description 2
- 238000011896 sensitive detection Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000005062 synaptic transmission Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011870 unpaired t-test Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- SMJRBWINMFUUDS-UHFFFAOYSA-N 2-thienylacetic acid Chemical compound OC(=O)CC1=CC=CS1 SMJRBWINMFUUDS-UHFFFAOYSA-N 0.000 description 1
- 102100033639 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 241000269627 Amphiuma means Species 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 102100033715 Apolipoprotein A-I Human genes 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 102000012192 Cystatin C Human genes 0.000 description 1
- 108010061642 Cystatin C Proteins 0.000 description 1
- 101100055841 Danio rerio apoa1 gene Proteins 0.000 description 1
- 101000733802 Homo sapiens Apolipoprotein A-I Proteins 0.000 description 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010036832 Prolactinoma Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000007792 alzheimer disease pathology Effects 0.000 description 1
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 1
- 230000006933 amyloid-beta aggregation Effects 0.000 description 1
- 230000007450 amyloidogenic pathway Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical class C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000010261 blood fractionation Methods 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 125000003178 carboxy group Chemical class [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- RZVXOCDCIIFGGH-UHFFFAOYSA-N chromium gold Chemical group [Cr].[Au] RZVXOCDCIIFGGH-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000695 excitation spectrum Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 238000005188 flotation Methods 0.000 description 1
- 238000002292 fluorescence lifetime imaging microscopy Methods 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000001119 image correlation spectroscopy Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000008449 language Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003923 mental ability Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 229910002055 micronized silica Inorganic materials 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 238000009116 palliative therapy Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 208000030153 prolactin-producing pituitary gland adenoma Diseases 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- BXEMXLDMNMKWPV-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1 BXEMXLDMNMKWPV-UHFFFAOYSA-N 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 150000003287 riboflavins Chemical class 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- DQJDBUPLRMRBAB-WZTVWXICSA-N tafamidis meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O1C2=CC(C(=O)O)=CC=C2N=C1C1=CC(Cl)=CC(Cl)=C1 DQJDBUPLRMRBAB-WZTVWXICSA-N 0.000 description 1
- TUGDLVFMIQZYPA-UHFFFAOYSA-N tetracopper;tetrazinc Chemical compound [Cu+2].[Cu+2].[Cu+2].[Cu+2].[Zn+2].[Zn+2].[Zn+2].[Zn+2] TUGDLVFMIQZYPA-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 238000000492 total internal reflection fluorescence microscopy Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000001419 two-dimensional polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 238000005019 vapor deposition process Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000016776 visual perception Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N2021/6417—Spectrofluorimetric devices
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
- G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1805466.8 | 2018-04-03 | ||
| GBGB1805466.8A GB201805466D0 (en) | 2018-04-03 | 2018-04-03 | Methods |
| PCT/EP2019/058206 WO2019192969A1 (en) | 2018-04-03 | 2019-04-01 | Method for the diagnosis of amyloid-associated diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112639470A true CN112639470A (zh) | 2021-04-09 |
Family
ID=62142284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980035259.0A Pending CN112639470A (zh) | 2018-04-03 | 2019-04-01 | 淀粉样物质相关疾病的诊断方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220026446A1 (ja) |
| EP (1) | EP3775884B1 (ja) |
| JP (1) | JP7389049B2 (ja) |
| CN (1) | CN112639470A (ja) |
| GB (1) | GB201805466D0 (ja) |
| WO (1) | WO2019192969A1 (ja) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL241595B1 (pl) * | 2020-02-12 | 2022-10-31 | Univ Warszawski | Sposób, zestaw oraz zastosowanie tioflawiny T do wykrywania monomerów i agregatów białka, tioflawina T do zastosowania w diagnozowaniu choroby związanej z agregacją białek oraz sposób generacji wzmocnionej emisji spontanicznej tioflawiny T |
| CN113008850B (zh) * | 2021-02-07 | 2022-02-25 | 首都医科大学宣武医院 | 诊断阿尔茨海默病的用途及诊断阿尔茨海默病的装置 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008030973A2 (en) * | 2006-09-06 | 2008-03-13 | The Board Of Regents Of The University Of Texas System | Methods and compositions for the detection of protein folding disorders |
| CN102429906A (zh) * | 2010-09-29 | 2012-05-02 | 国家纳米科学中心 | 氮杂环化合物在制备抑制淀粉样多肽毒性的药物中的用途 |
| US20160077110A1 (en) * | 2014-09-11 | 2016-03-17 | Board Of Regents Of The University Of Texas System | Detection of Misfolded Amyloid Beta Protein |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4223681B2 (ja) * | 1997-09-19 | 2009-02-12 | エボテック・アーゲー | 病原性タンパク質沈着の基礎構造の会合の測定方法 |
| JP2009168500A (ja) * | 2007-12-17 | 2009-07-30 | Olympus Corp | 分子の凝集検出方法及び凝集阻害剤のスクリーニング方法 |
-
2018
- 2018-04-03 GB GBGB1805466.8A patent/GB201805466D0/en not_active Ceased
-
2019
- 2019-04-01 US US17/044,199 patent/US20220026446A1/en active Pending
- 2019-04-01 WO PCT/EP2019/058206 patent/WO2019192969A1/en active Search and Examination
- 2019-04-01 JP JP2020554847A patent/JP7389049B2/ja active Active
- 2019-04-01 CN CN201980035259.0A patent/CN112639470A/zh active Pending
- 2019-04-01 EP EP19715084.0A patent/EP3775884B1/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008030973A2 (en) * | 2006-09-06 | 2008-03-13 | The Board Of Regents Of The University Of Texas System | Methods and compositions for the detection of protein folding disorders |
| CN102429906A (zh) * | 2010-09-29 | 2012-05-02 | 国家纳米科学中心 | 氮杂环化合物在制备抑制淀粉样多肽毒性的药物中的用途 |
| US20160077110A1 (en) * | 2014-09-11 | 2016-03-17 | Board Of Regents Of The University Of Texas System | Detection of Misfolded Amyloid Beta Protein |
Non-Patent Citations (1)
| Title |
|---|
| ANN TIIMAN ET.AL.: "《Heterogeneity and Turnover of Intermediates during Amyloid-β (Aβ) Peptide Aggregation Studied by Fluorescence Correlation Spectroscopy》", 《BIOCHEMISTRY》, vol. 54, no. 49, 16 November 2015 (2015-11-16), pages 7203 - 7211 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3775884C0 (en) | 2024-05-08 |
| WO2019192969A1 (en) | 2019-10-10 |
| JP2021519930A (ja) | 2021-08-12 |
| US20220026446A1 (en) | 2022-01-27 |
| GB201805466D0 (en) | 2018-05-16 |
| EP3775884B1 (en) | 2024-05-08 |
| EP3775884A1 (en) | 2021-02-17 |
| JP7389049B2 (ja) | 2023-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| De et al. | Soluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer’s disease progression | |
| Wildburger et al. | Diversity of amyloid-beta proteoforms in the Alzheimer’s disease brain | |
| Moors et al. | The subcellular arrangement of alpha-synuclein proteoforms in the Parkinson’s disease brain as revealed by multicolor STED microscopy | |
| Esparza et al. | Soluble amyloid-beta aggregates from human Alzheimer’s disease brains | |
| Kim et al. | Antibody-based magnetic nanoparticle immunoassay for quantification of Alzheimer’s disease pathogenic factor | |
| US6498017B2 (en) | Method for measuring the association of substructures of pathological protein depositions | |
| US20100105098A1 (en) | Methods of Identifying Disease Biomarkers in the Lense of the Eye | |
| JP6478987B2 (ja) | 表面ｆｉｄａの使用下でのタンパク質凝集体の測定方法 | |
| CN1198214A (zh) | 通过定量p97来诊断和监测阿尔海默氏病 | |
| Funke et al. | Single particle detection of Aβ aggregates associated with Alzheimer’s disease | |
| Tiiman et al. | Amyloidogenic nanoplaques in blood serum of patients with Alzheimer’s disease revealed by time-resolved thioflavin T fluorescence intensity fluctuation analysis | |
| US20100303805A1 (en) | Identification of small molecules recognized by antibodies in subjects with neurodegenerative diseases | |
| Schaffrath et al. | Patients with isolated REM-sleep behavior disorder have elevated levels of alpha-synuclein aggregates in stool | |
| Huang et al. | Raman spectrometric detection methods for early and non-invasive diagnosis of Alzheimer’s disease | |
| Uchihara et al. | Tangle evolution linked to differential 3-and 4-repeat tau isoform deposition: a double immunofluorolabeling study using two monoclonal antibodies | |
| Zhang et al. | Quantitative assessment of AD markers using naked eyes: point-of-care testing with paper-based lateral flow immunoassay | |
| CN112639470A (zh) | 淀粉样物质相关疾病的诊断方法 | |
| Chatterjee et al. | Detection of contactin-2 in cerebrospinal fluid (CSF) of patients with Alzheimer's disease using Fluorescence Correlation Spectroscopy (FCS) | |
| Gong et al. | Is liquid biopsy mature enough for the diagnosis of Alzheimer’s disease? | |
| Zheng et al. | Oral Mucosa Derived α− Synuclein as a Potential Diagnostic Biomarker for Parkinson′ s Disease | |
| Kulenkampff et al. | An antibody scanning method for the detection of α-synuclein oligomers in the serum of Parkinson's disease patients | |
| Funke et al. | Single-particle detection system for Aβ aggregates: adaptation of surface-fluorescence intensity distribution analysis to laser scanning microscopy | |
| Moors et al. | Subcellular orchestration of alpha-synuclein variants in Parkinson’s disease brains revealed by 3D multicolor STED microscopy | |
| CN117054664A (zh) | 用于诊断阿尔茨海默病的试剂盒及应用 | |
| Liang et al. | Nanoplasmonic fiber tip probe detects significant reduction of intracellular Alzheimer’s disease-related oligomers by curcumin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |